Erez Vigodman appointed Teva CEO

Erez Vigodman

"Globes" was the first to report that the Makhteshim Agan CEO would replace Jeremy Levin who was fired last October.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) today announced that Erez Vigodman has been appointed president and CEO. "Globes" was the first to report that Vigodman, 54, currently CEO Makhteshim Agan Industries Ltd. would replace Dr. Jeremy Levin who was fired last October following deep difference of opinion with the board of directors over the company's strategy.

Since then Eyal Desheh has been acting CEO and Vigodman will now assume his new position from February 11. Teva announced that Desheh will return to his previous post as EVP and CFO.

Teva chairman Dr. Phillip Frost said, “As a member of the Teva board since 2009, Erez has a deep understanding of the company and the industry in which it operates, putting him in a strong position to hit the ground running and deliver value for shareholders."

Teva said that Vigodman will step down as Makhteshim CEO on February 6.

Vigodman said, “I understand the challenges facing Teva and I am confident that, together with the management team, we can address these challenges and deliver on our commitment to creating value for our shareholders by expanding Teva's businesses and delivering long-term growth.”

Teva's new vice chairman Amir Elstein who led the special committee leading the CEO search, said, “Erez is the right person to lead Teva. We evaluated a comprehensive list of internal and external candidates as part of our rigorous search and Board process, engaging the international search firm Egon Zehnder. Erez stood out due to his impressive track record in transforming global and complex corporations and delivering breakthrough results. He is a change agent with an impressive strategic mindset and a proven ability to execute restructuring programs, build organizational momentum, expand successfully in emerging markets, and work with the capital markets."

Published by Globes [online], Israel business news - www.globes-online.com - on January 9, 2014

© Copyright of Globes Publisher Itonut (1983) Ltd. 2014

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Your name
Please insert your name
Content
Hyperlink in a new window Hyperlink Right Left underline italic bold Bulleted List Ordered List Face1 Face2 Face3 Face4 Face5 Face6
Your comment

Thanks
You comment was recieved and soon will be published.
In posting comments, I agree to abide by the Terms of Use
Globes encourages lively and frank debate, but posts that the editors consider merely abusive or otherwise inappropriate will be removed. Report inappropriate content
Thank you for posting your comment, which will be reviewed for publication.
Loading Comments...load
Load more comments
Erez Vigodman
Erez Vigodman
Yaron Daniely Replacing Ritalin

Alcobra has had two successful Nasdaq offerings this year as it develops an ADHD treatment with fewer side effects.

Twitter Facebook Linkedin RSS Newsletters